NasdaqGM - Nasdaq Real Time Price • USD
SCYNEXIS, Inc. (SCYX)
As of 11:52 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.2 | -0.1 | -0.16 | 0.01 |
| Low Estimate | -0.21 | -0.21 | -0.64 | -0.5 |
| High Estimate | -0.18 | 0.04 | 0.56 | 1.39 |
| Year Ago EPS | -0.71 | 2.46 | 1.39 | -0.16 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 300k | 5.3M | 36.17M | 38.82M |
| Low Estimate | -- | -- | 11.89M | 3.18M |
| High Estimate | 800k | 10.8M | 72.8M | 116.25M |
| Year Ago Sales | 1.13M | -- | 140.14M | 36.17M |
| Sales Growth (year/est) | -73.50% | -- | -74.20% | 7.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.28 | 1.55 | -0.15 | -0.2 |
| EPS Actual | -0.71 | 2.46 | -0.04 | -0.39 |
| Difference | -0.43 | 0.91 | 0.11 | -0.19 |
| Surprise % | -153.60% | 58.70% | 73.30% | -95.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.1 | -0.16 | 0.01 |
| 7 Days Ago | -0.2 | -0.1 | -0.16 | 0.01 |
| 30 Days Ago | -0.07 | -0.14 | 0.25 | 0.46 |
| 60 Days Ago | -0.07 | -0.14 | 0.25 | 0.46 |
| 90 Days Ago | -0.01 | -0.21 | 0.25 | 0.46 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 3 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SCYX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 71.80% | -- | -- | 1.30% |
| Next Qtr. | -104.10% | -- | -- | 10.60% |
| Current Year | -111.50% | -- | -- | 5.10% |
| Next Year | 106.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/15/2023 |
| Maintains | Guggenheim: Buy | 4/3/2023 |
| Reiterates | Ladenburg Thalmann: Buy | 4/3/2023 |
| Initiated | Guggenheim: Buy | 3/1/2023 |
| Maintains | HC Wainwright & Co.: Buy | 5/13/2022 |
Related Tickers
ASRT Assertio Holdings, Inc.
0.9264
+7.13%
COLL Collegium Pharmaceutical, Inc.
35.80
+3.05%
DCPH Deciphera Pharmaceuticals, Inc.
15.07
+3.33%
MEDXF Medexus Pharmaceuticals Inc.
1.1700
0.00%
BFRI Biofrontera Inc.
1.4597
+1.37%
ORGO Organogenesis Holdings Inc.
2.9600
-0.34%
IRWD Ironwood Pharmaceuticals, Inc.
8.25
+2.36%
ESPR Esperion Therapeutics, Inc.
2.0200
+5.74%
TLPH Talphera, Inc.
0.9750
+4.84%
PCRX Pacira BioSciences, Inc.
26.88
+2.99%